Rocky, thanks for all this mid year info/stats.
Unfortunately, interpretation of these not being my area of expertise, and at best being a long term average hack, I'm gonna put myself down in questioning my judgement/assessment going forward as not the most positive, as further dilution going forward seems in the cards?
ACTC is in such a fluid and dynamic situation given the: possible impact of october and subsequent data from clinicals; fom s. korea; from possible new partnering; from possible new CIRM funding; etc., etc., that It's hard to impossible to begin to see through it all.
I remain terribly excited about ACTC, but technicals and the lack of commercialization to date will probably almost always rule, imo, unless all hell breaks loose come october?
I don't have a feel for factors like any illegal naked shorting going on, nor the boards thinking on rs, etc?
There are so many imponderables.
One thing that's kinda comforting short term, if the US debt situation is not positively resolved come aug. 2, I think ACTC will hold up percentage -wise better than the most all fund stocks, to the degree that that's any consolidation.
